Abiomed (Nasdaq:ABMD) shares soared before hours on third-quarter results and the news of its acquisition by Johnson & Johnson (NYSE:JNJ). Johnson & Johnson announced this morning that it agreed to buy Abiomed for $16.6 billion. Shares of ABMD skyrocketed up more than 50% at $378.30 apiece in morning trading today. MassDevice‘s MedTech 100 Index, which includes […]
Abiomed
Johnson & Johnson to acquire Abiomed for $16.6B
Johnson & Johnson (NYSE:JNJ) announced today that it agreed to acquire Abiomed (Nasdaq:ABMD) for approximately $16.6 billion. Under the agreement, Johnson & Johnson intends to acquire through tender offer all outstanding Abiomed shares. That amounts to an upfront payment of $380 per share in cash. Johnson & Johson plans to complete the transaction before the […]
FDA approves Abiomed Impella RP Flex with SmartAssist for treating right heart failure
Abiomed (Nasdaq:ABMD) announced today that the FDA granted its Impella RP Flex with SmartAssist pre-market approval (PMA). Danvers, Massachusetts-based Abiomed designed the Impella RP Flex with SmartAssist to treat right heart failure. It does so for up to 14 days. The company intends to introduce Impella RP Flex in the U.S. through a controlled launch […]
5 top trends shaping the medtech industry
Ashley McEvoy is an industry veteran and the EVP and worldwide chair of Johnson & Johnson MedTech. Michael Minogue, another veteran, serves as chair, president and CEO of heart pump maker Abiomed. Together, the two bring a wealth of medtech industry knowledge to the table. They demonstrated that in a “CEOs Unplugged” discussion at AdvaMed’s […]
Abiomed reaches new regulatory milestone for its Impella pumps
Abiomed (Nasdaq:ABMD) announced that the FDA accepted and closed its post-approval study reports for its Impella heart pumps. Danvers, Massachusetts-based Abiomed’s study reports relate to Impella’s premarket approvals (PMA). The company said in a news release that the FDA’s action represents “another affirmation” of the safety and effectiveness of Impella heart pumps. Impella pumps treat […]
FDA clears Impella low-profile sheath from Abiomed
Abiomed (Nasdaq:ABMD) announced today that it received FDA 510(k) clearance for its Impella low-profile sheath. Danvers, Massachusetts-based Abiomed designed its sheath to maintain the same inner diameter as the existing 14 French (Fr) sheath used for Impella CP placement. However, the new sheath reduces the outer diameter by nearly 2 Fr. The sheath’s smaller size, […]
Abiomed Impella heart pump performs well in Japan study
Abiomed (Nasdaq:ABMD) announced today that a three-year study in Japan demonstrated positive results for its Impella heart pump. Danvers, Massachusetts-based Abiomed’s study is an update to 2020 interim analysis. Results were presented at TCT 2022 in Boston. The investigator-led study evaluated all Impella-supported patients across 109 hospitals in Japan. Of the 1,344 AMI cardiogenic shock […]
FDA approves new research around Abiomed Impella heart pumps
Abiomed (Nasdaq: ABMD) said today that FDA has approved clinical research into using Impella heart pumps in severe heart attack patients with cardiogenic shock. The FDA has approved the on-label Recover IV randomized controlled trial involving acute myocardial infarction (AMI) cardiogenic shock patients. The two-arm trial will assess whether Impella support before percutaneous coronary intervention […]
10 big earnings stories from the last quarter: How are medtech stocks doing now?
Economic uncertainty appears to have produced a wide variety of medtech earnings stories during the most recent round of quarterly results. Some medical device companies received massive boosts from their quarterly performance, while others saw their stocks sink amid missed projections and other various issues. The phrase “macroeconomic headwinds” was a common phrase. Medtech faces […]
Abiomed scales back revenue guidance amid strong dollar
Abiomed (Nasdaq: ABMD) today reported Q1 earnings that beat The Street, but the company is scaling back revenue projections amid tough foreign exchange rates for U.S. companies. The Danvers, Mass.–based maker of circulatory and oxygenation support devices earned $54.6 million, or $1.19 per share, off $277.1 million in sales for the quarter ended June 30, […]
Abiomed beats The Street in Q4 results
Abiomed (Nasdaq:ABMD) posted fourth-quarter results today that beat the overall consensus on Wall Street. The Danvers, Massachusetts-based company reported profits of $60.3 million, or $1.31 per share, on sales of $269.9 million for the three months ended December 31, for a bottom-line gain of 6.1% on sales growth of 11.86% compared with Q4 2021. Adjusted […]